Hong Kong Biotech Stock News

Ascletis Pharma (SEHK:1672) has attracted fresh attention after announcing ASC37, a once-monthly subcutaneous GLP-1R/GIPR/GCGR triple agonist for cardiometabolic diseases, discovered using its AI assisted and ultra long acting peptide platforms. See our latest analysis for Ascletis Pharma. The ASC37 announcement lands after a strong run in the shares, with a 90 day share price return of 56.58% and a year to date share price return of 23.96%. The 1 year total shareholder return of 249.14%...

Blue Moon Group Holdings (SEHK:6993) issued new earnings guidance, telling investors it expects at least a 50% reduction in its 2025 loss compared with the HK$749.3 million loss recorded for 2024. See our latest analysis for Blue Moon Group Holdings. That guidance landed alongside a 1 day share price return of 4.56% and a year to date share price return of 8.76% at HK$2.98. However, the 1 year total shareholder return of 13.58% and 5 year total shareholder return of 77.98% show that longer...

Why Sihuan Pharmaceutical’s latest filler approval matters for investors Sihuan Pharmaceutical Holdings Group (SEHK:460) recently reported that six additional specifications of its polylactic acid facial filler received approval from China’s National Medical Products Administration, expanding its medical aesthetics product range to allow more tailored anti aging treatments. See our latest analysis for Sihuan Pharmaceutical Holdings Group. The latest PLLA filler approvals come after a strong...

Chinese regulators have given Tencent Holdings (SEHK:700) and other large tech groups preliminary approval to prepare purchases of Nvidia's H200 AI chips. The in principle clearance signals possible progress on access to advanced AI hardware for Tencent within China’s existing controls on sensitive technology imports. Tencent recently reiterated its focus on AI development and open ecosystem partnerships at the World Economic Forum. Tencent is a major Chinese technology company with...

Why MicroPort Scientific’s latest guidance matters MicroPort Scientific (SEHK:853) has told investors it expects a turnaround to profitability in 2025, guiding to net profit of at least US$20 million after reporting an audited 2024 net loss of about US$268 million. See our latest analysis for MicroPort Scientific. The guidance appears to have arrived alongside a shift in sentiment, with a 1 month share price return of 18.17% and year to date share price return of 19.81%. The 1 year total...

Kuaishou Technology recently completed multi-currency fixed-rate senior unsecured bond offerings, raising about US$1.49 billion and CNY 3.50 billion with maturities extending to 2036, while reporting December 2025 monthly revenue above US$20 million. At the same time, its AI video-generation tool Kling surpassed 12 million monthly active users, underscoring how artificial intelligence is becoming a core pillar of Kuaishou’s business model and product appeal. We’ll now examine how the...

Earlier this year, Geely Holding Group outlined a new “One Geely” blueprint targeting global vehicle sales above 6.5 million by 2030, with new energy vehicles projected to account for three-quarters of volumes and overseas markets contributing more than one-third of deliveries. By tightly coordinating its brands and technology programs around green, intelligent and autonomous driving solutions, Geely is signaling a push to operate more like an integrated global technology group than a...

Why this dual drug news matters for CSPC Pharmaceutical Group (SEHK:1093) CSPC Pharmaceutical Group (SEHK:1093) has just reported two pipeline milestones, US and China trial approvals for its aldosterone synthase inhibitor SYH2072 in hypertension and a fresh China filing for a fixed dose diabetes combination. For investors, these updates highlight activity in both early clinical development and late stage commercial readiness. This helps frame how the stock might reflect CSPC's current...

Lenovo Group (SEHK:992) has just expanded its education and retail technology offerings, announcing new Chromebook models for classrooms alongside AI powered Smart Store Services and AI Retail Assistants aimed at retailers’ operations and customer interactions. See our latest analysis for Lenovo Group. These education and retail launches come after a tougher period for the shares, with a 90 day share price return of 23.26% decline and a 1 year total shareholder return of 3.02% decline. This...

Earlier this month, Akeso announced that China’s National Medical Products Administration accepted its supplemental New Drug Application for gumokimab (AK111), an anti‑IL‑17A antibody for active ankylosing spondylitis, supported by positive Phase III data. This milestone highlights Akeso’s expanding non‑oncology portfolio and the potential for gumokimab to address a large ankylosing spondylitis patient population in China. We’ll now examine how gumokimab’s sNDA acceptance, supported by...

Zylox-Tonbridge Medical Technology (SEHK:2190) recently hosted an Investor Open Day at its Zhuhai Innovation Center, showcasing its endovascular product portfolio to nearly 150 institutional investors and sell side analysts. See our latest analysis for Zylox-Tonbridge Medical Technology. The Investor Open Day comes after a strong run in the shares, with a 30 day share price return of 16.37% and a 1 year total shareholder return of 135.76%. This suggests momentum has been building rather than...

CIMC Enric Holdings (SEHK:3899) has moved to raise fresh capital by filing a follow-on equity offering of up to 79.7 million new shares at HK$9.79, representing approximately 3.92% of its existing issued share capital. See our latest analysis for CIMC Enric Holdings. The follow on offering lands after a strong run, with a 30 day share price return of 20.80% and a 90 day share price return of 33.97%. The 1 year total shareholder return of 60.49% and 5 year total shareholder return of 161.58%...

Why Pop Mart’s new buyback is back in focus Pop Mart International Group (SEHK:9992) has kicked off a sizeable share repurchase program, targeting up to 10% of its issued capital after shareholder approval, and the move has quickly sharpened market attention. See our latest analysis for Pop Mart International Group. The buyback news landed on a market already seeing a sharp swing in sentiment, with a 7 day share price return of 22.96% and a 1 year total shareholder return of 140.99% following...

Key Insights Significant insider control over Skyworth Group implies vested interests in company growth The largest...

Key Insights Significant control over VISEN Pharmaceuticals by public companies implies that the general public has...

With its stock down 15% over the past three months, it is easy to disregard TUHU Car (HKG:9690). But if you pay close...

Recent performance snapshot CK Hutchison Holdings (SEHK:1) has drawn investor attention after a strong share price move, with returns of 1.4% over the past day, 3.8% over the past week, and 13.6% over the past month. See our latest analysis for CK Hutchison Holdings. Set against a 1 year total shareholder return of 67.9% and a 22.8% 3 month share price return, the recent move suggests momentum has been building as investors reassess both growth potential and risks for CK Hutchison Holdings at...

Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. Mistakes are...

With a price-to-earnings (or "P/E") ratio of 34.4x Shanghai INT Medical Instruments Co., Ltd. ( HKG:1501 ) may be...

Most readers would already be aware that EPS Creative Health Technology Group's (HKG:3860) stock increased...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Ching Lee Holdings Limited's ( HKG:3728 ) price-to-earnings (or "P/E") ratio of 7.5x might make it look like a buy...

With a median price-to-earnings (or "P/E") ratio of close to 13x in Hong Kong, you could be forgiven for feeling...